Definitive Contract HHSN261200511017C
Award Date 9/16/05
Potential Completion Date 9/15/07
Potential Value $3M
Funding Federal Agency
Not listed Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Not listed Set-Aside Type
Total Small Business
Federal Contract Vehicle
- Not listed
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Emeryville, CA 94608, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed Similar Awards
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI) to Myriad RBM, Inc. for the development of a clinical automated multiplex affinity capture technology to detect low abundance cancer-related proteins and peptides. The contract has a firm fixed price of $1,126,627.00 and was awarded on September 28, 2007, with a scheduled completion date of June 27, 2010. As an SBIR Phase I contract, this award represents the initial research and...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract, valued at $185,116, is a firm-fixed-price definitive contract for research and development work. The contract was awarded on September 24, 2010 and has an ultimate completion date of June 23, 2011. As an SBIR Phase I contract, it is focused on the early-stage feasibility study of a...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Matrisome Bio, Inc. for the development of "Novel Theranostic Radioligands Targeting Disease-Specific Extracellular Matrix Components Specific to Tumor and Metastatic Lesions in Patients Suffering from Hereditary Breast and Ovarian Cancer (HBOC)." The contract has a firm fixed price of $354,456.00 and a completion date of September 14, 2026. As this...
- This is a $144,220 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Magarray, Inc. for the development of early diagnostic tools using nanotechnology-based imaging and sensing. The contract was awarded on September 28, 2007 and has a completion date of March 27, 2008. Magarray, Inc. is a for-profit manufacturer located in Mountain View, California. The contract is a firm fixed-price definitive contract, which...
- This federal contract award for $389,535 was made to Electronic Biosciences, Inc., a small business biotechnology company, by the National Cancer Institute (NCI) under the Small Business Innovation Research (SBIR) program. The contract is for the development of an "IDEAL AT-HOME PROSTATE SPECIFIC ANTIGEN (PSA) TESTING" solution, which aligns with NCI's mission to support innovative technologies for cancer diagnostics and prevention. The contract is a Firm Fixed Price, Definitive...
- The U.S. government's Department of Health and Human Services (HHS) awarded a $139,270 Small Business Innovation Research (SBIR) Phase I contract to Proveri, Inc. for the development of "Quantitative Tissue Imaging for Clinical Diagnosis and Prognosis of Prostate Cancer." The contract, with a completion date of March 30, 2010, is a firm fixed-price definitive contract set aside for small businesses. The contract supports early-stage research and development of innovative imaging...
- This is a $197,673 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a part of the Department of Health and Human Services (HHS), to Molecular Express, Inc., a minority-owned and self-certified small disadvantaged business. The contract is for the development of a commercial point-of-care device capable of electronically sensing tumor cells and molecular cancer biomarkers in a patient's circulating peripheral blood. This research project...
- This federal contract award, identified as HHSN261201200069C, was issued by the National Cancer Institute (NCI), a civilian agency, to Pharmaseq, Inc., a small business, for the development of a "Multiplex Prostate Cancer Serum Assay on RFID P-Chips" under the SBIR (Small Business Innovation Research) Program Phase I. The award, valued at $199,909.00 on a firm fixed-price basis, has a completed date of September 27, 2013. The contract is designated as a total small business set-aside.
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
- Malcova Inc., a small business specializing in advanced medical imaging technologies for breast cancer detection, was awarded a $2.0 million firm fixed price contract by the National Cancer Institute under the Small Business Innovation Research (SBIR) Program Phase II on September 18, 2023. This 27-month contract, set aside exclusively for small businesses, extends through September 17, 2025, and focuses on developing patient-derived anthropomorphic phantoms for automated objective assessment of...